Prescrire IN ENGLISH - HOME

Register online | Log in | My Prescrire

Issue contents

About Prescrire

n°129

July 2012

Prescrire International

Issue Contents

Editorial
Free Early signals	p.172
Hasty regulators gambled on aliskiren's harms and benefits

Marketing Authorisations
Belatacept (New Drug)	p.173-176
In kidney transplantation: more risky than ciclosporin


INN common stem: -piprazole	p.176


Aliskiren: negative trial data (Harms)	p.176
A do-not-use drug


Flurbiprofen without a prescription for dysmenorrhoea: rejected by French drugs agency (Regulation)	p.177
A wise decision


Sildenafil and pulmonary hypertension in children (New Indication)	p.178
First, do no harm


Topical fluticasone for infants from 3 months of age (New Indication)	p.179
Inadequate assessment


Prescrire's comments	p.179
Fluticasone and infants : a poor example


Amlodipine + aliskiren (Combination)	p.180
Still no evidence that aliskiren reduces morbidity or mortality


Naproxcinod (Application Withdrawn)	p.180
No authorisation in the European Union


Pioglitazone: European approval maintained despite the acknowledged risks (Harms)	p.181
Chaotic regulation

Adverse Effects
Calcium channel blockers + macrolides: elderly patients hospitalised for low blood pressure	p.182
Avoid erythromycin and clarithromycin


Free Domperidone: ventricular arrhythmia and sudden death	p.183
Do not use


Alcohol-based hand sanitizers: severe intoxication in children	p.184
Keep out of reach


NSAIDs: miscarriage (continued)	p.185
NSAIDs should not be used at any time during pregnancy


Vitamin E and prostate cancer	p.185
Unfavourable harm-benefit balance


Fluoroquinolones and tendon disorders: even after single-dose therapy	p.185
3 times more reports involved pefloxacin

Reviews
Paracetamol during pregnancy: no particular danger for the child	p.186-190


Paracetamol exposure in utero or during infancy: no increase in asthma	p.188-189

Outlook
Free Corporate influence over clinical research: considering the alternatives	p.191-194
Funding drug research independent of drug companies: a pipe dream or a public health necessity?


Free The exorbitant price of cancer drugs	p.195
No correlation with therapeutic benefits

Masthead
Free Masthead	p.170

The complete contents of
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated.